吉林大学学报(医学版) ›› 2021, Vol. 47 ›› Issue (1): 229-236.doi: 10.13481/j.1671-587x.20210132
收稿日期:
2020-07-24
出版日期:
2021-01-28
发布日期:
2021-01-27
通讯作者:
韩东梅,程光惠
E-mail:dmhan@jlu.edu.cn;chenggh@jlu.edu.cn
作者简介:
宋姗珊(1995-),女,吉林省长春市人,在读硕士研究生,主要从事肿瘤放射治疗方面的研究。
基金资助:
Received:
2020-07-24
Online:
2021-01-28
Published:
2021-01-27
摘要:
舌活动部癌是最常见的口腔癌,其主要治疗方式为手术及放射治疗(RT),舌活动部癌的RT包括体外放射治疗(EBRT)和组织间插植近距离放射治疗(ISBT)。早期舌活动部癌患者应用单纯ISBT或EBRT联合ISBT可在保证肿瘤局部控制(LC)率的同时保留舌功能,从而改善患者的生存质量;无法手术的中、晚期舌活动部癌患者采用EBRT联合ISBT的方式可进一步提高肿瘤LC率,并降低周围正常组织的受量;各期舌活动部癌术后具有局部复发危险因素的患者应用ISBT可有效提高肿瘤的LC率;局部复发性舌活动部癌患者可行ISBT或与EBRT联合的方式行挽救性治疗。现总结和探讨近年来国内外应用高剂量率(HDR)-ISBT治疗舌活动部癌的相关研究和应用进展,对HDR-ISBT治疗舌活动部癌的适应证、靶区勾画、处方剂量、正常组织剂量限值、相关临床结果和不良反应进行综述,以期为同行提供可靠的临床参考。
中图分类号:
宋姗珊,王学峰,刘宝财,韩东梅,程光惠. 舌活动部癌高剂量率组织间插植近距离放射治疗研究进展Research progress in high dose rate interstitial brachytherapy of mobile tongue cancer[J]. 吉林大学学报(医学版), 2021, 47(1): 229-236.
1 | KOVACS G.Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy[J]. J Contemp Brachytherapy,2015,6(4):404-416. |
2 | MAZERON J J, ARDIET J M,HAIE-MÉDERCHRISTINE C, et al.GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas[J]. Radiother Oncol,2009, 91(2):150-156. |
3 | BANSAL A, GHOSHAL S, OINAM A S, et al. High-dose-rate interstitial brachytherapy in early stage oral tongue cancer-15 year experience from a tertiary care institute[J]. J Contemp Brachytherapy, 2016, 8 (1):56-65. |
4 | CHEN S W, ZHANG Q , GUO Z M, et al. Trends in clinical features and survival of oral cavity cancer: fifty years of experience with 3,362 consecutive cases from a single institution[J]. Cancer Manag Res, 2018, 10:4523-4535. |
5 | KOVACS G,MARTINEZ-MONGE R, BUDRUKKAR A, et al. GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update-Improvement by cross sectional imaging based treatment planning and stepping source technology[J]. Radiother Oncol, 2017, 122(2): 248-254. |
6 | TAKÁCSI-NAGY Z, MARTÍNEZ-MONGUE R, MAZERON J J, et al.American Brachytherapy Society Task Group Report: Combined external beam irradiation and interstitial brachytherapy for base of tongue tumors and other head and neck sites in the era of new technologies[J]. Brachytherapy, 2017, 16(1): 44-58. |
7 | HAIE-MÉDER C, MAROUN P, FUMAGALLI I, et al. Pourquoi la curiethérapie reste-t-elle indispensable en 2017? [J].Cancer Radiother, 2018,22(4):307-311. |
8 | HELLEBUST T P. Place of modern imaging in brachytherapy planning[J]. Cancer Radiother, 2018,22(4):326-333. |
9 | AKIYAMA H,PESZNYAK C,BELA D, et al. Image guided high-dose-rate brachytherapy versus volumetric modulated arc therapy for head and neck cancer: A comparative analysis of dosimetry for target volume and organs at risk[J]. Radiol Oncol, 2018, 52(4) :461-467. |
10 | OTTER S J, STEWART A J, DEVLIN P M. Modern brachytherapy[J]. Hematol Oncol Clin North Am, 2019, 33(6):1011-1025. |
11 | TANDERUP K, MENARD C, POLGAR C, et al. Advancements in brachytherapy[J]. Adv Drug Deliv Rev, 2017, 109:15-25. |
12 | RUDOLTZ M S, PERKINS R S, LUTHMANN R W, et al. High-dose-rate brachytherapy for primary carcinomas of the oral cavity and oropharynx[J]. Laryngoscope, 1999, 109(12):1967-1973. |
13 | INOUE T, INOUE T, YOSHIDA K Y, et al. Phase Ⅲ trial of high-vs. low-dose-rate interstitial radiotherapy for early mobile tongue cancer[J]. Int J Radiat Oncol Biol Phys,2001,51(1):171-175. |
14 | PFISTER D G, SPENCER S, ADELSTEIN D, et al. Head and neck cancers, version 2. 2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020,18(7):873-898. |
15 | 李晔雄. 肿瘤放射治疗学[M].5版.北京:中国协和医科大学出版社, 2018:447-469. |
16 | OMURA K. Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma[J]. Int J Clin Oncol, 2014,19(3):423-430. |
17 | MANNELLI G, ARCURI F, AGOSTINI T, et al. Classification of tongue cancer resection and treatment algorithm[J]. J Surg Oncol, 2018,117(5):1092-1099. |
18 | STRNAD V. Treatment of oral cavity and oropharyngeal cancer.Indications, technical aspects, and results of interstitial brachytherapy[J]. Strahlenther Onkol,2004,180(11):710-717. |
19 | CHAKRABARTI B, GHORAI S, BASU B S,et al.Late nodal metastasis in early-stage node-negative oral cavity cancers after successful sole interstitial brachytherapy:an institutional experience of 42 cases in India[J]. Brachytherapy,2010,9(3):254-259. |
20 | FUKANO H, MATSUURA H, HASEGAWA Y, et al.Depth of invasion as a predictive factor for cervical lymph node metastasis in tongue carcinoma[J]. Head Neck,1997,19(3):205-210. |
21 | BALASUBRAMANIAN D, EBRAHIMI A, GUPTA R,et al.Tumour thickness as a predictor of nodal metastases in oral cancer: Comparison between tongue and floor of mouth subsites[J]. Oral Oncol,2014, 50(12):1165-1168 |
22 | POTHARAJU M,HEMANTHRAJ E,MUTHUKUMARAN M, et al.Long-term outcome of high-dose-rate brachytherapy and perioperative brachytherapy in early mobile tongue cancer[J]. J Contemp Brachytherapy, 2018, 10(1):64-72. |
23 | GANLY I, PATEL S, SHAH J. Early stage squamous cell cancer of the oral tongue:clinicopathologic features affecting outcome[J]. Cancer,2012,118(1): 101-111. |
24 | LIU J C, SOPKA D S, MEHRA R, et al. Early oral tongue cancer initially managed with surgery alone: Treatment of recurrence[J]. World J Otorhinolaryngol Head Neck Surg,2016, 2(4): 193-197. |
25 | PARIKH H K, RAO R S, SUKHTHANKAR P,et al. Surgery in early cancer of the oral tongue (T1-2). Wide excision versus hemiglossectomy[J]. Indian J Otolaryngol Head Neck Surg,1998, 50(4):349-353. |
26 | OKAMOTO, TAKASHI, AKIYAMA, et al. High-dose-rate interstitial brachytherapy for tongue cancer : a radiological and biological study from the perspective of late complications[J]. J Osaka Dent Univ, 2012, 46(1):57-62. |
27 | SHIM S J, CHA J, KOOM W S, et al. Clinical outcomes for T1-2N0-1 oral tongue cancer patients underwent surgery with and without postoperative radiotherapy[J]. Radiat Oncol,2010, 5(1):43-49. |
28 | STRNAD V, POTTER R, KOVACS G, et al. Practical handbook of brachytherapy,Chapter 18:ENT tumours[M]. Bremen-London Boston:UNI-MED Verlag,2014: 166-183. |
29 | PELLIZZON A C, SALVAJOLI J V, KOWALSKI L P, et al. Salvage for cervical recurrences of head and neck cancer with dissection and interstitial high dose rate brachytherapy[J]. Radiat Oncol,2006,1(1):27-43. |
30 | LAPEYRE M, BIAU J, RACADOT S, et al.Radiothérapie des cancers de la cavité buccale[J]. Cancer Radiother,2016, 20:S116-S125. |
31 | AKIYAMA H,YOSHIDA K,SHIMZUTANI K, et al. Dose reduction trial from 60 Gy in 10 fractions to 54 Gy in 9 fractions schedule in high-dose-rate interstitial brachytherapy for early oral tongue cancer[J]. J Radiat Res,2012,53(5):722-726. |
32 | NISHIOKA T, HOMMA A, FURUTA Y, et al. A novel approach to advanced carcinoma of the tongue: cases successfully treated with combination of superselective intra-arterial chemotherapy and external/high-dose-rate interstitial radiotherapy[J]. Jpn J Clin Oncol, 2006,36(12):822-826. |
33 | PEIFFERT D, COCHE-DEQUÉANT B, LAPEYRE M,et al. Curiethérapie des cancers de la tête et du cou: synthèse des recommandations européennes et principales indications[J].Cancer Radiother, 2018,22(4):359-366. |
34 | MARTÍNEZ-MONGE R, PAGOLA DIVASSÓN M, CAMBEIRO M, et al. Determinants of complications and outcome in high-risk squamous cell head-and-neck cancer treated with perioperative high–dose rate brachytherapy (PHDRB)[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):E245-E254. |
35 | 谷铣之,殷蔚伯. 肿瘤放射治疗学[M].4版. 北京:中国协和医科大学出版社, 2015:335-336. |
36 | MAYADEV J, BENEDICT S H, KAMRAVA M. Handbook of image-guided brachytherapy [M]. New York :Springer International Publishing, 2017:219-273. |
37 | YOSHIDA K , KOTSUMA T , AKIYAMA H , et al. A new implant device to prevent edema-associated underdosage in high-dose-rate interstitial brachytherapy of mobile tongue cancer[J]. J Contemp Brachytherapy, 2019, 11(6):573-578. |
38 | 谢丽娜,高诚宜,李 毅,等.精准放疗质控保证—位置/剂量监测技术研究进展[J].西安交通大学学报(医学版),2020,41(1):7-12. |
39 | 岳 堃,姚 原,贾晓斌,等.基于smart LMC算法的动态调强技术在舌癌术后放疗中的剂量学研究[J].中国医学物理学杂志,2019,36(11):1255-1260. |
40 | AKIYAMA H, YOSHIDA K, YAMAZAKI H, et al. High-dose-rate interstitial brachytherapy for mobile tongue cancer: preliminary results of a dose reduction trial[J]. J Contemp Brachytherapy, 2014, 6(1):10-14. |
41 | YAMAZAKI H. Comparison of three major radioactive sources for brachytherapy used in the treatment of node negative T1-T3 oral tongue cancer : influence of age on outcome[J]. Anticancer Res, 2007,27(1b):491-497. |
42 | KAKIMOTO N, INOUE T, INOUE T, et al. Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer[J]. Radiother Oncol, 2003, 68(2):123-128. |
43 | SHNTOS M A,GUINOT J L,TORTAJADA M I, et al. High-dose-rate interstitial brachytherapy boost in inoperable locally advanced tongue carcinoma[J].Brachytherapy,2017,68(6):123-128. |
44 | CISEK P, KIESZKO D, BRZOZOWSKA A, et al. Image-guided high-dose-rate brachytherapy of head and neck-a case series study[J]. J Contemp Brachytherapy, 2016, 8(6):544-553. |
45 | BHALAVAT R, CHANDRA M, PAREEK V, et al. High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art-a single institute experience[J].J Contemp Brachytherapy, 2017, 9(2):124-131. |
46 | GUINOT J L, SANTOS M, TORTAJADA M I, et al. Efficacy of high-dose-rate interstitial brachytherapy in patients with oral tongue carcinoma[J]. Brachytherapy, 2010, 9(3):227-234. |
47 | KAZEMIAN A,BABAEI M,LASHKARI M, et al. Adjuvant high-dose-rate brachytherapy in the management of oral cavity cancers: 5 years of experience in Iran[J]. J Contemp Brachytherapy, 2017, 9(4):323-329. |
48 | LEE S U, CHO K H, MOON S H, et al. Clinical outcome of high-dose-rate interstitial brachytherapy in patients with oral cavity cancer[J]. Radiat Oncol J,2014, 32(4):238-246. |
49 | PLATTEAUX N, DIRIX P, VANSTRAELEN B, et al. Outcome after re-irradiation of head and neck cancer patients[J]. Strahlenther Onkol,2011,187(1):23-31. |
50 | HIDEYA Y, KEN Y, YASUO Y, et al. High dose rate brachytherapy for oral cancer[J]. J Radiat Res, 2013,54(1):1-17. |
[1] | 刘璐,张天夫,王晓峰,孔晨飞. 多配体蛋白聚糖1对舌鳞状细胞癌CAL27细胞迁移、侵袭和细胞周期的调控作用[J]. 吉林大学学报(医学版), 2021, 47(1): 59-65. |
[2] | 张楚, 郝苗, 王会俞, 王晓峰, 张天夫. 奥沙利铂对人舌鳞癌CAL27细胞增殖和凋亡的影响及其机制[J]. 吉林大学学报(医学版), 2020, 46(02): 233-239. |
[3] | 王会俞, 张天夫, 郝苗, 张楚, 王晓峰. 人参果多糖对人舌鳞癌CAL27细胞增殖的抑制作用及其机制[J]. 吉林大学学报(医学版), 2020, 46(02): 248-253. |
[4] | 李浩渤, 杜勇, 陈勇, 李文静. Notch 1对舌麟状细胞癌Tca8113细胞表皮生长因子受体表达的影响及其意义[J]. 吉林大学学报(医学版), 2017, 43(04): 715-719. |
[5] | 孙宾, 王越, 尹国相, 杜宝霞, 于子莹, 张伟. 游离上臂外侧皮瓣修复舌癌患者术后软组织缺损的临床应用[J]. 吉林大学学报(医学版), 2017, 43(02): 408-411. |
[6] | 段秀梅, 李烁烯, 明智慧, 张丛笑, 刘文书. 舌鳞状细胞癌组织中Cks1、Skp2和p27kip1蛋白的表达及其临床意义[J]. 吉林大学学报(医学版), 2015, 41(02): 347-351. |
[7] | 杨彩玲,张景航,张应花,任铭新,刘进忠,崔卫刚. 埃克替尼通过p38-MAPK信号通路对涎腺腺样囊性癌ACC-M细胞的凋亡诱导作用[J]. 吉林大学学报(医学版), 2014, 40(04): 820-823. |
[8] | 李 翔,张 斌,马 竟,高 琦,史 毅. Akt抑制剂MK2206对舌鳞癌TCA-8113细胞增殖和凋亡的影响及其作用机制[J]. 吉林大学学报(医学版), 2014, 40(03): 616-625. |
[9] | 董肖婷,张斌,刘硕硕,郭婷婷,潘良朋,贾妮. 抑癌基因PTEN真核表达载体的构建及其在人舌鳞癌SCC-4细胞系中的表达[J]. 吉林大学学报(医学版), 2013, 39(2): 282-285. |
[10] | 郭婷婷, 张 斌,刘佳柏,刘硕硕, 董肖婷. 抑癌基因PTEN对舌鳞状细胞癌侵袭性及上皮-间质转化相关蛋白表达的影响[J]. 吉林大学学报(医学版), 2013, 39(1): 70-73. |
[11] | 1. 吉林大学口腔医院药剂科,吉林 长春130041;2. 吉林大学口腔医院黏膜病科,吉林 长春130041;3. 吉林大学第一医院口腔科,吉林 长春130021. 化疗药物对舌癌细胞增殖能力的影响[J]. J4, 2006, 32(4): 672-674. |
[12] | 黄 汉,李方遒,张 斌,马 竟. Livin和细胞色素C在舌鳞状细胞癌组织中的表达及其临床意义[J]. 吉林大学学报(医学版), 2013, 39(6): 1233-1236. |
[13] | 刘治慧, 杨巍. 橙皮素对舌癌细胞的生长抑制作用及其机制[J]. 吉林大学学报(医学版), 2015, 41(03): 558-562. |
[14] | 史毅, 金晓红, 吴伟忠, 霍安, 周伟, 黄汉. 补骨脂乙素对舌鳞状细胞癌Tca8113细胞增殖的抑制作用和凋亡诱导作用及其机制[J]. 吉林大学学报(医学版), 2016, 42(04): 725-730. |
[15] | 韩春耀, 张斌, 马雪, 刘明媛, 薛中原, 郝丽静, 葛树卿. 沉默α-catulin基因的人舌鳞状细胞癌TSCCA细胞模型的建立[J]. 吉林大学学报(医学版), 2016, 42(03): 481-485. |
|